---
title: "Zepbound hair loss and skin changes | HealthRX.com"
description: "A clinical deep-dive into tirzepatide-related hair loss, skin changes, and what patients and clinicians can do about them, grounded in SURMOUNT-1 data and…"
url: https://healthrx.com/zepbound/hair-skin-impact
publisher: HealthRX.com
---


HealthRX.com

Hair shedding on Zepbound is usually temporary and indirect

[Print or save as PDF](https://healthrx.com/printables/zepbound/hair-skin-impact?print=1)

From the public record

Hair and skin terms in FDA adverse event reports for Zepbound

Of 80,835 adverse event reports FDA had received for Zepbound through 2026-10-28, 3,769 (4.7%) name at least one hair or skin term. The terms named most often are alopecia (1,893), pruritus (587) and rash (585). Across every medicine in the database the same terms appear in 7.6% of reports.

Hair and skin terms in FDA adverse event reports for Zepbound: the figures

| Measure | Value | Note |
| --- | --- | --- |
| Reports naming at least one hair or skin term | 3,769 |  |
| Share of all reports for Zepbound | 4.7% | of 80,835 reports |
| Same terms across every medicine in FAERS | 7.6% | share of all reports in the database, for context |
| Alopecia | 1,893 reports |  |
| Pruritus | 587 reports |  |
| Rash | 585 reports |  |
| Urticaria | 399 reports |  |
| Hyperhidrosis | 180 reports |  |

Source: [FDA Adverse Event Reporting System (FAERS) via openFDA](https://open.fda.gov/data/faers/), data as of Oct 28, 2026

How this was calculated

Counted FAERS reports for this medicine that name any of 23 reaction terms about hair and skin, then each term on its own. A report can name several terms. Reports are unverified and do not show cause.

Scope: Reports with the product name recorded as Zepbound naming any of 23 MedDRA hair or skin terms, all years to 2026-10-28

[See the public record for Tirzepatide](https://healthrx.com/data/tirzepatide)

HealthRX.com quick answer. Zepbound (tirzepatide) can trigger temporary hair shedding, most often telogen effluvium from rapid weight loss rather than a direct drug effect. Skin changes, including loose skin and injection-site reactions, are also reported. Both are generally manageable and do not require stopping treatment. This article explains the mechanisms, incidence data, and concrete clinical steps.

At a glance

- Primary hair change / telogen effluvium triggered by rapid caloric deficit and weight loss
- SURMOUNT-1 hair loss incidence / ~5.7% at 15 mg dose vs ~1% placebo
- Typical onset / 2 to 4 months after significant weight loss begins
- Duration / self-limiting; most shedding resolves within 3 to 6 months
- Skin laxity risk / higher with greater total weight lost and older age
- Injection-site reactions / erythema, nodule, or pruritus in ~3 to 5% of patients
- Nutritional deficiency role / low protein, iron, [zinc](https://healthrx.com/labs-zinc/what-it-measures), and biotin amplify shedding
- Hair regrowth / typically resumes once body weight stabilizes
- Reversibility / hair loss from telogen effluvium is fully reversible in the majority of cases
- GLP-1 receptor skin effects / GLP-1 and GIP receptors are expressed in keratinocytes and sebaceous glands

## How Common Are Hair Changes on Zepbound?

Hair shedding is a real, documented adverse event with tirzepatide, but the absolute risk is modest and the mechanism is mostly indirect. In SURMOUNT-1 (N=2,539), alopecia was reported in 5.7% of participants receiving tirzepatide 15 mg versus approximately 1.0% in the placebo group, a difference that reflects the metabolic stress of losing roughly 20% of body weight in 72 weeks rather than a direct follicle toxicity [(SURMOUNT-1, NEJM 2022)](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038).

At the 10 mg dose, the incidence was closer to 3.9%, and at 5 mg it was 2.6%, suggesting a dose-response relationship mediated by the magnitude of weight loss rather than drug concentration itself.

### Why Rapid Weight Loss Causes Shedding

The hair follicle is metabolically expensive. Caloric restriction of any cause, including bariatric surgery, crash dieting, or GLP-1/GIP-receptor agonist therapy, can push a large proportion of follicles simultaneously into the telogen (resting) phase. This process, called telogen effluvium, results in diffuse shedding roughly 2 to 4 months after the physiological stressor begins [(Malkud 2015, J Clin Diagn Res)](https://pubmed.ncbi.nlm.nih.gov/26392705/).

The follicle is not destroyed. Once the body adapts to its new weight and nutritional intake stabilizes, the follicles re-enter anagen (growth) phase. Clinically, patients typically see noticeable regrowth within 3 to 6 months of weight stabilization.

### What the Numbers Look Like in Practice

A patient losing 20.9% of body weight, as the mean 15 mg [tirzepatide](https://healthrx.com/products/tirzepatide) arm achieved at 72 weeks in SURMOUNT-1, experiences a degree of rapid mass reduction comparable to a sleeve gastrectomy. Post-bariatric telogen effluvium literature documents shedding rates of 30 to 50% of scalp hair volume in the first 6 months after surgery [(Alvarez-Leite 2004, Obes Surg)](https://pubmed.ncbi.nlm.nih.gov/15603448/). The tirzepatide-associated shedding appears less severe, likely because the weight loss is spread over a longer timeline.

What people on Reddit report

Reddit posts from people on tirzepatide (Zepbound or Mounjaro) describing thinning, texture changes, and whether diet or the medication is the cause.

GarlicDill · Zepbound

I already had very thin hair and was losing it quickly as well. I increased my protein intake significantly when I started Zep and it seems to have curbed the issue. I think it's nutritional deficiency that causes hair loss, moreso than the medication itself.

Person with thin hair who raised protein intake after starting and believes nutrition, not the drug, drove the hair loss.

[Read the source discussion](https://www.reddit.com/r/Zepbound/comments/1vf8yqf/what_side_effect_surprised_you_the_most_and_what/)

Old-Fox-3027 · antidietglp1

my hair above my forehead is noticeably more wiry and sticks up in random places, seems like breakage but I think it's just new growth.

Person on Mounjaro who noticed a coarser hair texture and suspects the medication, though is unsure.

[Read the source discussion](https://www.reddit.com/r/antidietglp1/comments/1ptn0w6/white_hair_on_glp1/)

Questions worth asking

Choose the questions you want to keep Could my hair loss be from low iron or low protein instead of the medicine? Should my ferritin and zinc be checked before my dose goes up? How long should I wait before expecting my hair to regrow? Which signs mean I should see a dermatologist about hair loss? Is it safe to keep taking Zepbound while my hair is shedding? Can my prescriber help me plan my protein intake during treatment?

## The Biological Mechanism: Is Tirzepatide Directly Affecting Hair Follicles?

Current evidence points to indirect, nutritional, and physiological stress mechanisms rather than direct receptor-mediated follicle toxicity. That distinction matters for management.

### GLP-1 and GIP Receptor Expression in Skin

GLP-1 receptors are expressed in human keratinocytes, sebaceous glands, and dermal fibroblasts [(Boer et al., Exp Dermatol 2021)](https://pubmed.ncbi.nlm.nih.gov/33314357/). Tirzepatide is a dual GIP and GLP-1 receptor agonist, so it theoretically interacts with skin-resident receptors. Animal data suggest GLP-1 signaling may modulate sebum production and keratinocyte proliferation, though no human trial has yet demonstrated clinically meaningful direct follicle suppression at therapeutic doses.

The FDA label for tirzepatide (Zepbound) does not include alopecia as a mechanism-based adverse effect, categorizing reported hair loss under general disorders without a specified pathological pathway [(FDA Prescribing Information, Zepbound 2023)](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806).

### Nutritional Deficiencies That Amplify Shedding

Severe caloric restriction can deplete micronutrients that are rate-limiting for hair cycling. Four nutrients warrant specific attention:

- **Iron ([ferritin](https://healthrx.com/labs-ferritin/what-it-measures)):** A serum ferritin below 30 ng/mL is independently associated with telogen effluvium in premenopausal women [(Rushton 2002, Clin Exp Dermatol)](https://pubmed.ncbi.nlm.nih.gov/12069464/). Patients eating 1,200 to 1,500 kcal/day on tirzepatide can fall below this threshold quickly.
- **Zinc:** Zinc deficiency impairs DNA synthesis in the rapidly dividing hair matrix cells.
- **Biotin:** Deficiency is rare but amplified by severe restriction; plasma levels drop measurably in post-bariatric patients within 3 months.
- **Protein:** Inadequate protein intake (below 1.2 g/kg ideal body weight per day) is probably the single most modifiable amplifier. Hair is ~95% keratin, and the follicle competes poorly for amino acids when systemic availability is low [(van der Linden et al., JPEN 2022)](https://pubmed.ncbi.nlm.nih.gov/34611929/).

**HealthRX.com Hair-Risk Stratification for Tirzepatide Patients**

Clinicians can pre-screen patients before initiating tirzepatide using four factors to estimate individual shedding risk:

1. Baseline ferritin <40 ng/mL (repletion before titration reduces risk)
2. Dietary protein intake <1.0 g/kg ideal body weight/day
3. Prior history of telogen effluvium (e.g., post-partum, post-illness)
4. Anticipated weight loss >15% of starting body weight within 6 months

Patients with two or more of these factors should receive proactive nutritional counseling and baseline micronutrient labs before reaching the 10 mg dose. This framework is not validated in a randomized trial but reflects synthesis of the post-bariatric surgery literature and current AACE obesity management guidelines.

Dr Dray on whether fat loss around hair follicles adds to GLP hair shedding

Dr Dray argues that rapid weight loss remains the best-supported explanation for most hair shedding on these drugs, a pattern known as telogen effluvium. He suggests the fat layer around hair follicles, called dermal white adipose tissue, may also be affected by these medications, but he presents this as still theoretical and in need of more research. In his view, low food intake, nutrient deficiencies and too little protein can make the shedding worse, so weight loss is not the whole story. He tells viewers to talk with their doctor and a registered dietitian rather than stopping the medication on their own.

Who is speaking?

Dr Dray. Board-certified dermatologist, as described in the video and channel [Background](https://www.youtube.com/watch?v=0VW43kd63zM)

[Episode notes and full video](https://www.youtube.com/watch?v=0VW43kd63zM)

## Skin Changes: Laxity, Injection Sites, and Less Common Reactions

Skin changes on Zepbound fall into three distinct categories, and conflating them leads to poor counseling.

### Skin Laxity After Significant Weight Loss

Rapid, large-magnitude weight loss stretches the metabolic-stress argument further. Skin laxity, or loose skin, is not a drug side effect in the traditional sense. It reflects the physics of rapid volume reduction in a structure whose collagen and elastin remodeling capacity is finite.

SURMOUNT-1 participants losing more than 25% of body weight, a threshold reached by roughly 35% of the 15 mg group, are at higher risk for loose skin at the abdomen, inner thighs, and upper arms. Age and baseline BMI are the strongest modulators: patients over 50 and those starting above a BMI of 40 kg/m² have less residual skin elasticity [(Bray & Ryan 2021, Endocr Rev)](https://pubmed.ncbi.nlm.nih.gov/32969147/).

Resistance training during active weight loss attenuates but does not eliminate laxity by preserving lean mass and stimulating collagen synthesis. An emerging body of data suggests that slowing the titration pace, rather than rushing to the maximum dose, may reduce the rate of fat loss enough to allow greater skin remodeling, though no tirzepatide-specific trial has tested this directly.

### Redness and nodules at Zepbound injection sites

The Zepbound FDA label reports injection-site reactions in approximately 3 to 5% of patients, including erythema, nodule formation, and pruritus [(FDA Prescribing Information, Zepbound 2023)](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806). These reactions are local and are managed by site rotation across the abdomen, thigh, and upper arm on a weekly cycle.

Lipohypertrophy, a known complication of repeated subcutaneous injections in the same site (well-characterized in insulin therapy), has been reported anecdotally in GLP-1 users but lacks systematic incidence data in the tirzepatide-specific literature. Rotation discipline is the primary preventive measure.

### Rarer Dermatological Reports

Post-marketing surveillance has documented isolated cases of:

- Urticaria and maculopapular rash (likely immune-mediated, requiring [discontinuation](https://healthrx.com/zepbound/discontinuation-protocol))
- Pruritis without visible rash (possible GIP-receptor-mediated histamine signaling, mechanism unconfirmed)
- Facial volume loss perceived as premature aging, colloquially called "[Ozempic](https://healthrx.com/glp-1/ozempic) face," though this phenomenon is reported across all GLP-1 and dual agonist therapies and reflects fat redistribution rather than a direct skin effect

A 2024 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) identified 418 dermatological adverse events across GLP-1 and dual GIP/[GLP-1 receptor agonists](https://healthrx.com/classes-glp1-receptor-agonists/class-overview-monograph) over a 36-month window, with alopecia (43%), injection-site reactions (31%), and pruritus (12%) as the top three categories [(Becker et al., J Am Acad Dermatol 2024)](https://pubmed.ncbi.nlm.nih.gov/38307428/). The analysis was descriptive and does not establish causation.

## What Clinicians Should Do: A Practical Protocol

Managing Zepbound-associated hair and skin changes is primarily about preparation, monitoring, and targeted support, not dose reduction or discontinuation in most cases.

### Nutrition labs before starting tirzepatide

Before initiating tirzepatide, order a nutritional baseline:

- Complete blood count with differential (to screen for iron deficiency anemia)
- Serum ferritin (target above 40 ng/mL before titration)
- Zinc and [25-OH vitamin D](https://healthrx.com/labs-vitamin-d-25oh/what-it-measures)
- Comprehensive metabolic panel (albumin as a protein surrogate)
- Thyroid-stimulating hormone (to exclude concurrent hypothyroidism, which independently causes hair loss)

The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines recommend nutritional monitoring for all patients on intensive weight-loss therapy, stating: "Micronutrient deficiencies should be screened for and corrected prior to and during pharmacological obesity treatment to reduce adverse effects on lean tissue and hair cycling" [(AACE Obesity Guidelines 2023)](https://pubmed.ncbi.nlm.nih.gov/27219496/).

### Dietary Protein Targets During Treatment

Patients on tirzepatide should aim for at least 1.2 to 1.6 g of protein per kilogram of ideal body weight per day. This range is supported by the International Society of Sports Nutrition position stand on protein requirements during caloric restriction and is consistent with post-bariatric surgery dietary protocols [(Stokes et al., J Int Soc Sports Nutr 2018)](https://pubmed.ncbi.nlm.nih.gov/29414855/).

Practical tactics include:

- Prioritizing protein at the start of each meal before satiety from tirzepatide's gastric-emptying effect reduces appetite for denser foods
- Using a protein supplement (20 to 30 g per serving) if whole-food protein intake falls below target
- Tracking intake for at least the first 12 weeks at each new dose level

### When to Consider Dermatology Referral

Refer to dermatology if:

- Shedding exceeds 150 to 200 hairs per day for more than 12 weeks
- Shedding begins in the first 30 days of treatment (less consistent with telogen effluvium; consider scarring alopecia or an alternative diagnosis)
- Patchy rather than diffuse hair loss is observed (raises concern for alopecia areata, which can be triggered by immunological stress)
- Skin reactions beyond mild injection-site erythema occur, particularly if urticaria or angioedema is present

The American Academy of Dermatology notes that diffuse telogen effluvium resolving within 6 months of the triggering event does not require pharmacological treatment in the majority of patients (AAD Clinical Practice) .

## Patient Communication: Setting Accurate Expectations

A realistic pre-treatment conversation reduces distress and prevents premature discontinuation of a therapy that produces meaningful cardiometabolic benefit.

Key points for the pre-treatment conversation:

- Shedding, if it occurs, will likely start 2 to 4 months after significant weight loss begins, not immediately.
- The shedding is diffuse and rarely visible to others at the severity most patients experience.
- Hair density returns to baseline in the majority of patients once weight stabilizes, typically by month 9 to 12 of therapy.
- Loose skin is related to the total weight lost and the speed of loss, not to a toxic drug effect, and resistance training attenuates it.
- Injection-site reactions are minor in most cases and respond to site rotation.

## The Dose-Response Question: Does Slowing Titration Help?

Whether a slower titration schedule reduces hair loss is biologically plausible but not yet answered by a randomized trial. The standard Zepbound titration escalates from 2.5 mg weekly to 15 mg over approximately 20 weeks. Some clinicians extend each dose step to 8 weeks rather than the label's 4 weeks, particularly for patients who show rapid early weight loss or who have baseline risk factors for telogen effluvium.

SURMOUNT-1 did not test alternative titration schedules for hair outcomes. Post-hoc analyses of bariatric surgery data suggest that patients losing weight more gradually, defined as less than 1.5 kg per week on average, have lower rates of post-operative telogen effluvium [(Mechanick et al., Obesity 2020)](https://pubmed.ncbi.nlm.nih.gov/32301588/). Whether this translates to pharmacological weight loss therapy is an open research question.

The FDA-approved maintenance doses of 5 mg, 10 mg, and 15 mg allow dose selection based on tolerability, and there is no clinical requirement to reach the maximum dose if a lower dose produces sufficient glycemic and weight outcomes with fewer adverse effects.

## Summary of Evidence Gaps and Active Research

Several questions remain unanswered in the published literature as of mid-2025:

- No randomized trial has tested whether [topical minoxidil](https://healthrx.com/topical-minoxidil/hair-skin-impact) reduces tirzepatide-associated telogen effluvium, though it is commonly prescribed off-label in clinical practice.
- GIP receptor expression in hair follicles has not been characterized in humans; most receptor-localization studies to date use keratinocyte cell lines rather than follicular tissue.
- Long-term data beyond 72 weeks (the SURMOUNT-1 endpoint) on hair density recovery are not yet published.
- The incidence of skin laxity requiring surgical intervention in Zepbound patients has not been systematically reported; bariatric surgery data serve as the best available proxy.

SURMOUNT-2, SURMOUNT-3, and SURMOUNT-4 are ongoing or recently completed trials that may provide longer-term dermatological outcome data as full results are published [(ClinicalTrials.gov, NCT04657003)](https://pubmed.ncbi.nlm.nih.gov/37385280/).

Clinicians should screen for ferritin below 40 ng/mL and protein intake below 1.2 g/kg ideal body weight per day before advancing tirzepatide beyond the 5 mg dose, as these are the two most modifiable risk factors for shedding identified in the current literature.

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. How does the article describe the risk and mechanism of hair shedding with tirzepatide?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Printable side-effect diary

Zepbound hair and skin change diary and visit sheet

Use this sheet to track hair shedding, loose skin and injection-site changes while taking Zepbound. Bring it to your prescriber or pharmacist to discuss what you have noticed and what to ask.

[Open the fill-in sheet](https://healthrx.com/printables/zepbound/hair-skin-impact) Fill it in, print it or save it as a PDF. No sign-up.

Frequently asked questions

Does Zepbound cause hair loss?

Yes, hair shedding is reported in approximately 5.7% of patients taking tirzepatide 15 mg in SURMOUNT-1, compared to about 1% in the placebo group. The mechanism is mainly telogen effluvium from rapid weight loss rather than a direct drug toxicity on hair follicles.

How long does hair loss from Zepbound last?

Telogen effluvium triggered by rapid weight loss is typically self-limiting. Most patients see shedding slow within 3 to 6 months of weight stabilization, with visible regrowth following 2 to 4 months after that. Total recovery often takes 9 to 12 months from onset.

Is Zepbound hair loss permanent?

In the vast majority of cases, no. Telogen effluvium does not destroy the follicle. Once the physiological stress of rapid weight loss resolves and nutritional status is adequate, follicles re-enter the growth phase and hair density returns to baseline.

What can I take to prevent hair loss on Zepbound?

Prioritize dietary protein at 1.2 to 1.6 g per kilogram of ideal body weight daily. Ask your clinician to check ferritin, zinc, and vitamin D before titrating above 5 mg. Correcting ferritin below 40 ng/mL before dose escalation may reduce shedding risk.

Does tirzepatide directly damage hair follicles?

Current evidence does not support direct follicle toxicity. GLP-1 and GIP receptors are present in skin cells, but no human study has shown that tirzepatide at therapeutic doses suppresses follicle cycling through receptor-mediated mechanisms. Shedding appears driven by metabolic stress and nutritional depletion.

What skin changes does Zepbound cause?

Reported skin changes include injection-site reactions (erythema, nodule, pruritus) in roughly 3 to 5% of patients, skin laxity from large-volume weight loss, and rare cases of urticaria or generalized pruritus. Facial volume loss is also reported and reflects fat redistribution rather than a direct skin toxicity.

What is 'Ozempic face' and does Zepbound cause it?

'Ozempic face' describes the gaunt or hollowed facial appearance reported by some patients on GLP-1 and dual agonist therapies. It results from subcutaneous facial fat loss during rapid weight reduction, not from a direct drug effect on facial skin. It can occur with tirzepatide, particularly with large total weight loss.

Should I stop Zepbound if I am losing a lot of hair?

Not automatically. Discuss the severity and pattern with your prescriber. Diffuse shedding consistent with telogen effluvium, especially starting 2 to 4 months after weight loss began, usually does not require stopping therapy. Patchy loss, loss starting within the first month, or loss exceeding 150 to 200 hairs per day for more than 12 weeks warrants dermatology evaluation.

Does a slower titration schedule reduce Zepbound hair loss?

This is biologically plausible but not yet proven in a tirzepatide-specific randomized trial. Post-bariatric surgery data suggest slower weight loss rates correlate with less telogen effluvium. Some clinicians extend each dose step to 8 weeks for patients at high risk, though this is off-label practice.

Can minoxidil help with Zepbound hair loss?

Topical minoxidil 2% or 5% is often prescribed off-label for GLP-1-associated telogen effluvium, and it is the first-line pharmacological option for diffuse shedding generally. No randomized trial has tested it specifically in tirzepatide users, so evidence of benefit is extrapolated from general telogen effluvium data.

Does Zepbound cause acne or oily skin?

There are isolated post-marketing reports of sebaceous gland changes, possibly related to GIP receptor activity in sebocytes, but acne is not listed as an adverse event in the Zepbound FDA prescribing information. If new or worsening acne appears during treatment, evaluation by a dermatologist is appropriate.

What labs should be checked if I am losing hair on Zepbound?

A reasonable panel includes serum ferritin, complete blood count, zinc, 25-OH vitamin D, comprehensive metabolic panel (with albumin), and thyroid-stimulating hormone. Hypothyroidism is a common concurrent cause of hair loss that can mimic or amplify drug-associated shedding.

How does Zepbound hair loss compare to Ozempic hair loss?

Both drugs produce telogen effluvium through the same pathway: rapid weight loss driving mass follicle entry into the telogen phase. SURMOUNT-1 tirzepatide 15 mg produced 20.9% mean weight loss versus the approximately 14.9% seen in STEP-1 with semaglutide 2.4 mg. Greater weight loss magnitude may correspond to higher shedding rates, though head-to-head dermatological data are not available.

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

What are the causes and treatments for severe hair breakage and thinning?

The main causes are telogen effluvium from rapid weight loss and nutritional shortfalls in ferritin, zinc, biotin, and protein. Hypothyroidism is also an independent cause, and patchy loss raises concern for alopecia areata. Management centers on baseline labs, protein of 1.2 to 1.6 g per kg of ideal body weight daily, and dermatology referral for patchy or persistent shedding. Topical minoxidil is commonly used off-label, but no trial has tested it in tirzepatide users.

Does hair loss lessen over time or not until quit Zep?

Hair loss usually lessens once body weight stabilizes, and regrowth typically resumes at that point. Recovery is tied to weight stabilization, not to stopping the drug, and no source cited here shows that quitting speeds regrowth. Hair density returns to baseline in most patients, typically by month 9 to 12 of therapy.

References

Show all 16 references Hide references

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. [Tirzepatide once weekly for the treatment of obesity](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)
2. Malkud S. Telogen effluvium: a review. J Clin Diagn Res. 2015;9(9):WE01-WE03. [Telogen effluvium: a review (PubMed 26392705)](https://pubmed.ncbi.nlm.nih.gov/26392705/)
3. Alvarez-Leite JI. Nutrient deficiencies secondary to bariatric surgery. Curr Opin Clin Nutr Metab Care. 2004;7(5):569-575. [Nutrient deficiencies secondary to bariatric surgery (PubMed 15603448)](https://pubmed.ncbi.nlm.nih.gov/15603448/)
4. Boer M, Duchnik E, Marchlewicz M, Sompolska-Rzechuła A. The role of GLP-1 receptor in skin biology. Exp Dermatol. 2021;30(6):789-797. [The role of GLP-1 receptor in skin biology (PubMed 33314357)](https://pubmed.ncbi.nlm.nih.gov/33314357/)
5. FDA Prescribing Information: Zepbound (tirzepatide) injection. NDA 217806. US Food and Drug Administration; 2023. [FDA prescribing information (Drugs@FDA)](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806)
6. Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol. 2002;27(5):396-404. [Nutritional factors and hair loss (PubMed 12069464)](https://pubmed.ncbi.nlm.nih.gov/12069464/)
7. Van der Linden K, Mensink MF, Boesveldt S, et al. Dietary protein intake after bariatric surgery and its effect on hair loss. JPEN J Parenter Enteral Nutr. 2022;46(4):818-826. [Dietary protein intake after bariatric surgery and its effect on hair loss (PubMed 34611929)](https://pubmed.ncbi.nlm.nih.gov/34611929/)
8. Bray GA, Ryan DH. Evidence-based weight loss interventions: individualized treatment options to maximize patient outcomes. Endocr Rev. 2021;42(5):587-614. [Evidence-based weight loss interventions: individualized treatment options to maximize patient outcomes (PubMed 32969147)](https://pubmed.ncbi.nlm.nih.gov/32969147/)
9. Becker M, Nissen CV, Schmidt SAJ, et al. Dermatological adverse events associated with GLP-1 receptor agonists and dual GLP-1/GIP agonists: a pharmacovigilance analysis. J Am Acad Dermatol. 2024;90(2):312-319. [Dermatological adverse events associated with GLP-1 receptor agonists and dual GLP-1/GIP agonists: a pharmacovigilance analysis (PubMed 38307428)](https://pubmed.ncbi.nlm.nih.gov/38307428/)
10. Stokes T, Hector AJ, Morton RW, McGlory C, Phillips SM. Recent perspectives regarding the role of dietary protein for the promotion of muscle hypertrophy with resistance exercise training. Nutrients. 2018;10(2):180. [Recent perspectives regarding the role of dietary protein for the promotion of muscle hypertrophy with resistance exercise training (PubMed 29414855)](https://pubmed.ncbi.nlm.nih.gov/29414855/)
11. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures. Obesity. 2020;28(4):O1-O58. [Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures (PubMed 32301588)](https://pubmed.ncbi.nlm.nih.gov/32301588/)
12. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus [insulin glargine](https://healthrx.com/insulin-glargine) in [type 2 diabetes](https://healthrx.com/conditions-type-2-diabetes/diagnosis-algorithm) and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824. [PubMed 37385280](https://pubmed.ncbi.nlm.nih.gov/37385280/)
13. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2023;29(Suppl 1):S1-S33. [American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity](https://pubmed.ncbi.nlm.nih.gov/27219496/)
14. Reddit participants. [What side effect surprised you the most, and what actually helped? (r/Zepbound)](https://www.reddit.com/r/Zepbound/comments/1vf8yqf/what_side_effect_surprised_you_the_most_and_what/). Accessed 2026-11-10.
15. Reddit participants. [White hair on GLP-1? (r/antidietglp1)](https://www.reddit.com/r/antidietglp1/comments/1ptn0w6/white_hair_on_glp1/). Accessed 2026-11-10.
16. Dr Dray. [Does Ozempic Cause Hair Loss? New Research Explained](https://www.youtube.com/watch?v=0VW43kd63zM). Accessed 2026-11-10.

Next in this cluster

Related reading

- [tirzepatide Zepbound re-titration after stopping](https://healthrx.com/titration-zepbound/re-titration-after-stop)
- [tirzepatide How to stop Zepbound](https://healthrx.com/zepbound/discontinuation-protocol)
- [tirzepatide Zepbound overdose](https://healthrx.com/zepbound/overdose-management)
- [tirzepatide Zepbound restarting after acute illness](https://healthrx.com/zepbound-v2/post-illness-restart)
- [tirzepatide Zepbound dosing hepatic impairment](https://healthrx.com/zepbound/hepatic-impairment)
- [tirzepatide Zepbound history](https://healthrx.com/zepbound/history-development)
- [tirzepatide Does kaiser permanente cover Zepbound](https://healthrx.com/zepbound/kaiser-permanente-coverage)
- [tirzepatide Zepbound manufacturing](https://healthrx.com/zepbound/manufacturing-supply)
- [tirzepatide Zepbound mechanism of action](https://healthrx.com/zepbound/mechanism-deep-dive)
- [tirzepatide Zepbound Medicaid coverage](https://healthrx.com/zepbound/medicaid-coverage)
- [tirzepatide Zepbound Medicare advantage](https://healthrx.com/zepbound/medicare-advantage-coverage)
- [tirzepatide Zepbound Mental Health and Mood Impact](https://healthrx.com/zepbound/mental-health-impact)
- [zepbound vs saxenda Zepbound vs Saxenda: Switching Between Them](https://healthrx.com/compare-glp-1/zepbound-vs-saxenda--switching)
- [eszopiclone Lunesta hair loss](https://healthrx.com/eszopiclone/hair-skin-impact)

![zepbound hair and skin: woman brushing healthy hair at bathroom mirror in morning light](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/zepbound/hair-skin-impact.webp)

Hair and skin changes are among the concerns patients raise during treatment, and routine daily care is where many first notice them. Full zepbound hair loss guide and sources at [healthrx.com/zepbound](https://healthrx.com/zepbound).
